XML 69 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY (Details) - USD ($)
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Operating Expenses      
Director fees including bonus (excluding Chairman’s bonus) $ 707,385 $ 278,224 $ 122,101
Chairman’s bonus 1,160,347
Auditor’s Remuneration (refer to Note 20) [1] 349,665 131,511 53,402
Legal and Professional fees 1,143,300 343,422 195,433
(Gain)/Loss on disposal of leases (179)
FX Gains and losses (13,577) 200,061 200,061
Depreciation $ 2,423 $ 1,512 $ 212
[1] This has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the company’s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements. Refer to note 20 where details of auditor’s remuneration has been disclosed. This has no impact on the primary financial statements.